NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Health Technology Evaluation

Equality impact assessment – Scoping

**Trifluridine–tipiracil with bevacizumab for treating metastatic colorectal cancer after 2 systemic treatments [ID6298]**

The impact on equality has been assessed during this evaluation according to the principles of the NICE Equality scheme.

|  |
| --- |
| 1. Have any potential equality issues been identified during the scoping process (draft scope consultation and scoping workshop discussion), and, if so, what are they? |
| No |

|  |
| --- |
| 1. What is the preliminary view as to what extent these potential equality issues need addressing by the Committee? |
| n/a |

|  |
| --- |
| 1. Has any change to the draft scope been agreed to highlight potential equality issues? |
| No |

|  |
| --- |
| 1. Have any additional stakeholders related to potential equality issues been identified during the scoping process, and, if so, have changes to the stakeholder list been made? |
| No |

**Approved by Associate Director (name):** Emily Crowe **Date:** 22/09/2023